Standout Papers

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diab... 2017 2026 2020 2023 469
  1. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial (2017)
    Christopher Sorli, Shin‐ichi Harashima et al. The Lancet Diabetes & Endocrinology

Immediate Impact

4 from Science/Nature 97 standout
Sub-graph 1 of 22

Citing Papers

Stroke
2024 Standout
Tirzepatide for Obesity Treatment and Diabetes Prevention
2024 Standout
2 intermediate papers

Works of George Tsoukas being referenced

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
2017 Standout

Author Peers

Author Last Decade Papers Cites
George Tsoukas 555 292 170 14 654
Francis Chun Chung Chow 644 291 183 16 833
Elizabeth Round 458 176 135 12 629
Pedro Mezquita‐Raya 326 250 111 30 738
Jeffrey Unger 711 363 194 14 817
Vlado Perkovic 469 136 154 11 620
Charles Atisso 789 454 251 17 834
Michaël J.B. van Baar 623 226 298 11 728
Richard Pratley 623 177 210 9 812
Desirée Thielke 574 357 120 12 654
J.P. Gutai 513 119 46 18 719

All Works

Loading papers...

Rankless by CCL
2026